報價延遲最少15分鐘:2024/12/23 22:14 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.62 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
13.50/-1.52
|
|
企業價值
3.14M
|
| 資產負債 |
|
每股賬面淨值
1.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. |